Purpose of review
To review the 2009/2010 literature on pediatric genitourinary tumors and highlight the most significant publications.
Recent findings
New techniques such as gene expression profiling, PET, nephron-sparing surgery, and stem cell transplantation are being incorporated into contemporary treatments for pediatric patients with genitourinary tumors. Biologic markers are increasingly being used to help with risk stratification of patients. WT1 mutation and 11p15 loss of heterozygosity have been associated with relapse in very low-risk Wilms tumors treated with surgery alone and may help reduce the use of chemotherapy in some children. Discussion continues on the use of fusion gene status to risk stratify alveolar rhabdomyosarcoma. Meta-analysis of the use of high-dose chemotherapy with autologous hematopoetic stem cell rescue in patients with relapsed Wilms tumor and rhabdomyosarcoma suggests that some patients may benefit more from conventional salvage chemotherapy. New agents are needed for patients with high-risk and relapsed disease to improve outcomes. Summary In general, the prognosis for patients with pediatric genitourinary tumors is favorable. The elucidation of the molecular abnormalities in these tumors is determining risk stratification, treatment strategies, and candidates for new drug development. Recent data have validated previous findings in patients with very low-risk Wilms tumors (stage I favorable histology, <2 years old, and tumor weight < 550 g) that histologic and molecular differences may identify two groups with different risks of relapse [4] . Analysis for mutation of WT1, CTNNB1, WTX, 11p15 LOH, and for H19DMR and KvDMR1 methylation have shown that patients with WT1 mutation and 11p15 LOH were associated with relapse in patients with very low-risk Wilms tumors who did not receive chemotherapy (P ¼ 0.004 and P < 0.001, respectively) [5 ] . Favorable histology stage I and II patients with no LOH who do not qualify for surgery alone are treated with vincristine and dactinomycin for seven cycles (regimen EE-4A). If LOH of 1p and 16q is found, doxorubicin is added to the vincristine and dactinomycin for nine cycles (regimen DD4-A). Stage III patients with no LOH are also treated with DD4-A with radiation therapy added.
Keywords
More intensive chemotherapy is indicated for higher risk patients. These include stage III disease with LOH of 1p and 16q, and stage IV disease. Chemotherapy includes vincristine, dactinomycin, and doxorubicin with cyclophosphamide and etoposide added in addition to radiation therapy. Recent data from the Italian pediatric oncology cooperative group (AIEOP) suggest that it may be useful to separate stage III patients into those with positive and negative lymph nodes, as this was prognostic of outcome in their patient population [6 ] . Patients with stage IV disease with pulmonary lesions and no LOH who completely respond to chemotherapy at week 6 are treated with DD4-A with no pulmonary radiation. Patients with stage IV focal anaplasia and stage II-IV diffuse anaplasia are treated with 30 weeks of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and radiation therapy.
Approximately 5-7% of patients with Wilms tumor will have bilateral disease. Nephron-sparing approaches facilitated by preoperative chemotherapy should be used for those with bilateral disease, and in those with syndromes that predispose to late renal failure.
Twenty-five to 50% of patients who relapse after initial treatment for unilateral Wilms tumor can be salvaged. Ifosfamide/carboplatin/etoposide, cyclophosphamide/ etoposide, and carboplatin/etoposide are commonly used salvage regimens [7] . Some centers have used high-dose chemotherapy (HDC) with autologous hema-topoetic stem cell rescue (ASCR) as consolidation for salvage therapy [8, 9] . However, a recent meta-analysis comparing salvage chemotherapy with or without radiation therapy vs. chemotherapy followed by HDC with ASCR suggests that conventional salvage therapy may be better for most patients, but could be considered for stage III-IV patients with a lung-only relapse [10 ].
Molecular genetics
The molecular genetics of Wilms tumor is complex, with multiple genes involved (Table 1) . LOH for chromosomes 1p and/or 16q and high telomerase expression are adverse prognostic factors. Mutations of the Wilms tumor genes WT1 (11p13), WTX (Xq11.1), and CTNNB1 (3p22.1), are cumulatively detected in approximately one third of Wilms tumors [11] . These and other genes play a role in WNT signaling [12, 13] .
WT1 encodes a transcription factor that may act as a tumor suppressor or, when over expressed, as an oncogenic protein [14 ] . Patients with mutated WT1 have an increased risk of bilateral disease and recurrent disease. Another relatively high-risk group of patients are those with constitutional 11p15 abnormalities (WT2), which may result in a variety of clinical phenotypes including Beckwith-Wiedemann syndrome. Constitutional 11p15 abnormalities have been found in 3% of patients with sporadic (nonsyndromic) Wilms tumor and confer a higher risk of tumor recurrence [15] .
The WTX gene on the X chromosome is mutated in 7-29% of Wilms tumors [16] . WTX has been shown to 298 Genitourinary system
Key points
The prognosis for patients with pediatric genitourinary tumors is favorable. Molecular markers are increasingly becoming incorporated with traditional risk stratification, and contemporary clinical trials are incorporating these new risk criteria into treatment algorithms. WT1 mutation and 11p15 loss of heterozygosity have been associated with relapse in very low-risk Wilms tumors treated with surgery alone and may help reduce the use of chemotherapy in some children.
Meta-analysis of the use of high-dose chemotherapy with autologous hematopoetic stem cell rescue in patients with relapsed Wilms tumor and rhabdomyosarcoma suggests that some patients may benefit more from conventional salvage chemotherapy. New agents are needed for patients with high-risk and relapsed disease to improve outcomes.
act as a tumor suppressor gene by negatively regulating WNT/b-catenin signal transduction [17] . Germline mutations of WTX cause osteopathia striata congenital with hyperostosis and craniofacial malformations. Interestingly, these patients do not appear to be predisposed to developing Wilms tumors or other malignancies, despite loss-of-function mutations of this tumor suppressor gene [18] .
Other pediatric renal tumors
Although they are collectively less common than Wilms tumor, many other pediatric renal tumors occur including congenital mesoblastic nephroma, renal cell carcinoma (RCC), renal medullary carcinoma, clear cell sarcoma, anaplastic sarcoma, rhabdoid tumor, primitive neuroectodermal tumor, desmoplastic small round cell tumor, and intrarenal neuroblastoma [19 ] . These non-Wilms tumors occur more frequently in children less than 6 months or greater than 12 years of age. Surgery is the mainstay of therapy for these non-Wilms tumors, although some may benefit from adjuvant chemotherapy [19 ] . Tissue diagnosis is also critical, as imaging studies are not able to make a definitive diagnosis. Pediatric RCC has biological and clinical differences compared with adult RCC. In general, children with RCC have a better prognosis than adults with RCC [20]. The small molecule tyrosine kinase inhibitors sorafenib, sunitinib, and temsirolimus and the monoclonal antibody bevacizumab have promise as adjuvant therapies for RCC [20] . COG is prospectively studying high-risk renal tumors with a risk-adopted treatment approach utilizing six different treatment approaches based on diagnosis and stage (protocol AREN0321). This protocol is also in conjunction with the COG Renal Tumor Biology and Classification Study (AREN03B2), which provides central pathology review.
Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) originates from immature mesenchymal cells and can commonly affect bladder, prostate, and paratesticular sites in children. The perineum, vulva, vagina, and uterus are less common sites [21 ] .
Diagnosis and treatment
Genitourinary RMS can present with a painless scrotal/ inguinal swelling, pelvic mass, vaginal mass or bleeding, or hematuria/urinary obstruction. Biopsy with adequate tissue sampling for diagnosis and classification is important in diagnosis. There are two main histologic subtypes, embyronal and alveolar. Embyronal RMS (ERMS) is more common than alveolar (ARMS) histology in primary genitourinary sites. Primary surgical resection is difficult in some genitourinary RMS, particularly pelvic tumors. For patients with paratesticular primary sites and enlarged nodes on CT and those at least 10 years of age (even with a normal CT), staging ipsilateral retroperitoneal lymph node dissection is important because of the high rate of regional metastasis [22 ] .
Both pretreatment staging and clinical grouping are important in treatment planning, as they have been shown to correlate with clinical outcome. Pretreatment staging is based on the TNM system and includes primary tumor site, tumor size (5 or >5 cm), regional lymph node status, and metastatic disease. In combination with stage and histology, the COG also assigns treatment according to postsurgical grouping classification, based on residual disease following surgery. Some patients, particularly patients with pelvic primaries, may have residual tumor at the end of treatment. Aggressive resection of residual pelvic disease can cause significant morbidity. Group III patients treated on protocol intergroup rhabdomyosarcoma study IV (IRS-IV) with chemotherapy and radiation with or without surgery for local control had no increased risk of 5-year failure-free survival or death in patients with a partial or no response compared with the patients with a complete response (CR) [25] . A recent retrospective look at patients on the IRS-IV showed 93% of patients with a CR had no viable tumor at their second look procedure, and 41% of those without a CR had no viable tumor [26 ] .
Patients with high-risk and relapsed disease continue to have a poor prognosis. High-risk patients have a 3-year disease-free survival (DFS) of less than 30%, and DFS is even lower for patients with relapsed disease. Time to relapse appears to be prognostic for RMS with 4-year survival of 16% (relapse <6 months from end of therapy), 30% (relapse between 6-12 months after therapy), and 46% (relapse >12 months after therapy) in relapsed ERMS compared with 8, 6, and 23% in ARMS, respectively [27 ] . New strategies are needed to improve survival in these patients. A randomized phase II window trial of irinotecan with vincristine in patients with first relapse or progression on therapy suggests that these may be useful agents in future studies [28] . Therapies such as HDC with SCR [29, 30] have been used. A recent Cochrane review did not show a benefit of HDC compared with conventional relapse therapy, although only a few nonrandomized studies were available for analysis [31] . Newer biologic agents such as the proteasome inhibitor bortezomib and agents that target insulin-like growth factor 1 receptors show some promise [32] .
Molecular biology of rhabdomyosarcoma
The more aggressive ARMS is associated with two reciprocal translocations: t(2;13)(q35;q14) and t(1;13)(p36;q14), which generate fusions of paired box gene (PAX3) or PAX7, and FOXO1 (also known as forkhead homolog 1 rhabdomyosarcoma), respectively (Table 1) . The PAX3-FOXO1 fusion is present in approximately 70% of cases of ARMS; the PAX7-FOXO1 fusion is present in approximately 10-20% of cases of ARMS and has a more favorable prognosis compared with those with the PAX3-FOXO1 fusion. Embryonal RMS (ERMS) is associated with an 11p15.1 LOH and has a more favorable prognosis compared with ARMS. Fusion-negative ARMS has been shown to have a similar gene expression pattern to ERMS, and may also have similar clinical outcomes [33 ] . However, more data are needed to clarify whether this will be a useful prognostic factor and studies are currently underway retrospectively assessing FOXO1 rearrangement as well as PAX3-FOXO1 and PAX7-FOXO1 fusion status for ARMS [34] . Molecular classification of RMS-utilizing gene expression profiling and LOH analysis combined with immunohistochemistry is highly reproducible and more accurate than histopathology alone [35] . The integrin-linked kinase (ILK) gene has been shown to act as an oncogene in ARMS and, paradoxically, as a tumor suppressor gene in ERMS [36] . ILK inhibition and muscle-specific micro-RNAs that can promote differentiation of rhabdomyoblasts are under investigation [37] .
Testicular tumors
Primary testicular tumors are rare in children. A bimodal age distribution correlates with the observation that prepubertal tumors are generally distinct from those seen in adolescents, who have more adult like tumors [38] . The differential diagnosis for a painless scrotal mass in a child/ adolescent includes leukemia, RMS, and a primary testicular tumor [germ cell tumor (GCT) or nongerm cell]. Scrotal ultrasound remains the imaging modality of choice [39 ] . Yolk sac tumors (endodermal sinus tumors) and teratomas are the most common primary prepubertal testicular tumors. Embryonal carcinomas, choriocarcinoma, and mixed malignant GCTs may occur in older children (typically teenagers). Gonadoblastoma, Leydig cell, and Sertoli cell tumors are rare in children. Prior to radical inguinal orchiectomy, a serum a-fetoprotein (AFP) and b-human choriogonadotropin should be obtained. Ageadjusted AFP values should be used. Due to low rates of nodal involvement in children, SIRLND is reserved for cases with persistently elevated tumor markers or persistent retroperitoneal lymphadenopathy following chemotherapy. SALL4 is a new diagnostic marker that will aid pathologists in classifying testicular GCTs [40] . For GCTs requiring chemotherapy, platinum-based regimens result in excellent long-term survival [38] .
Late effects
Despite the overall favorable prognosis for patients with Wilms tumor, it is now clear that survivors are at increased risk of death for many years. Early deaths are more commonly due to relapse. Over time, however, late effects from therapy become a more common cause of mortality. These include second malignant neoplasms, heart failure, end-stage renal disease, and pulmonary disease [41 ] . There is a high incidence of late radiation morbidity in patients undergoing adjuvant radiation therapy for Wilms tumor [42 ] . Knowledge of these late effects is not only driving current treatment approaches but also highlighting the importance of careful long-term follow-up [43] . The general health of Wilms tumor survivors is worse compared with siblings, but their psychological health is relatively good [44] . Other late effects suffered by survivors of pediatric genitourinary tumors include bladder dysfunction, hypertension, musculoskeletal deformities, and reproductive problems [45] .
Conclusion
The molecular genetics of pediatric genitourinary tumors continues to shed light into the pathogenesis of these tumors and may provide future targets for treatment. Molecular markers are increasingly becoming incorporated with traditional risk stratification, and contemporary clinical trials are incorporating these new risk criteria into treatment algorithms. Newer targeted therapies have the promise of improving outcomes in higher risk or relapsed patients, and may help overall reduce long-term treatment complications.
